| Left ventricular dysfunction |
Cardiomyopathy or myocarditis |
Anthracyclines (e.g., doxorubicin, aunorubicin, epirubicin, idarubicin), antiangiogenic agents (e.g., bevacisumab, sunitinib, sorafenib), alkylating agents (e.g., cyclophosphamide, cisplatin), monoclonal antibodies (e.g., trastuzumab, lapatinib), tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sunitinib, sorafenib, lapatinib) |
| Arrhythmias |
QT prolongation, bradycardia, heart block; Atrial arrhythmias; Ventricular arrhythmias or sudden cardiac death |
Taxanes, arsenic trioxide, tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sunitinib, sorafenib, lapatinib), anthracyclines(e.g., doxorubicin, aunorubicin, epirubicin, idarubicin) |
| Coronary artery disease |
Acute coronary syndromes (included acute myocardial infarction); Chronic ischemic heart disease |
Antimetabolites (e.g., gemcitabine, cytarabine), cisplatin, taxanes, thalidomide, bevacisumab, radiotherapy |
| Pericardial disease |
Pericarditis (effusive or constrictive form) |
Radiotherapy |
| Hypertension |
New-onset or worsening |
Vascular endothelial growth factor inhibitors, antiangiogenic agents (e.g., bevacisumab, sunitinib, sorafenib), cisplatin, interleukins, interferon |
